Inhibition of PAK2 in endothelial cells suppresses tumor angiogenesis and promotes immune sensitization through CXCL10
RNA-seq (gene expression) · mouse · 24 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 24 samples: 3 × LLC tumor, CT-PAK2EC, vs 3 × LLC tumor, KO-PAK2EC, vs 3 × HUVEC, siCT, vs 3 × HUVEC, siPAK2,Groups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Inhibition of PAK2 in endothelial cells suppresses tumor angiogenesis and promotes immune sensitization through CXCL10Cell reports · 2026
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE312096_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1372162 and SRA study SRP650328. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 4 replicated groups read from 24 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9337681 LLC tumor, CT-PAK2EC, 1 LLC tumor, CT-PAK2EC,
- GSM9337682 LLC tumor, CT-PAK2EC, 2 LLC tumor, CT-PAK2EC,
- GSM9337683 LLC tumor, CT-PAK2EC, 3 LLC tumor, CT-PAK2EC,
- GSM9337684 LLC tumor, KO-PAK2EC, 1 LLC tumor, KO-PAK2EC,
- GSM9337685 LLC tumor, KO-PAK2EC, 2 LLC tumor, KO-PAK2EC,
- GSM9337686 LLC tumor, KO-PAK2EC, 3 LLC tumor, KO-PAK2EC,
- GSM9337687 HUVEC, siCT, 1 HUVEC, siCT,
- GSM9337688 HUVEC, siCT, 2 HUVEC, siCT,
- GSM9337689 HUVEC, siCT, 3 HUVEC, siCT,
- GSM9337690 HUVEC, siPAK2, 1 HUVEC, siPAK2,
- GSM9337691 HUVEC, siPAK2, 2 HUVEC, siPAK2,
- GSM9337692 HUVEC, siPAK2, 3 HUVEC, siPAK2,
- GSM9337693 HUVEC, siCT, 1.1
- GSM9337694 HUVEC, siCT, 2.1
- GSM9337695 HUVEC, siCT, 3.1
- GSM9337696 HUVEC, siPAK2, 1.1
- GSM9337697 HUVEC, siPAK2, 2.1
- GSM9337698 HUVEC, siPAK2, 3.1
- GSM9337699 HUVEC, siCXCL10, 1.1
- GSM9337700 HUVEC, siCXCL10, 2.1
- GSM9337701 HUVEC, siCXCL10, 3.1
- GSM9337702 HUVEC, siPAK2-siCXCL10, 1.1
- GSM9337703 HUVEC, siPAK2-siCXCL10, 2.1
- GSM9337704 HUVEC, siPAK2-siCXCL10, 3.1
- GSE311908 A targetable developmental program co-regulates angiogenesis and immune evasion [RNA-Seq] 42 samples shares angiogenesis
- GSE212524 Rnf20 levels modulate the VEGF-Notch signaling circuits during sprouting angiogenesis 50 samples shares angiogenesis
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.